Genmab ASMEX:GMABN 92 EBITDA Margin % is 24.00% as of Mar. 2026, which is 52% below its 10-year median of 50.15. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Genmab AS ranks better than 89.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genmab AS's EBITDA for the
three
months ended in Mar. 2026 was MXN3,877 Mil. Genmab AS's Revenue for the
three
months ended in Mar. 2026 was MXN16,157 Mil. Therefore, Genmab AS's EBITDA margin for the quarter that ended in Mar. 2026 was 24.00%.
Genmab AS (MEX:GMABN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genmab AS EBITDA Margin % Related Terms
Genmab AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genmab AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genmab AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genmab AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (MEX:GMABN) has a EBITDA Margin % of 24.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genmab AS and its competitors. This is 52% below median its historical median of 50.15. Over the past decade, Genmab AS's EBITDA Margin % has ranged from 32.98 to 64.50. According to the industry distribution chart, Genmab AS ranks #96 out of 944 companies in the Biotechnology industry, placing it in the top 10.2%.
Is Genmab AS's EBITDA Margin % too high?
Genmab AS's current EBITDA Margin % of 24.00% is 52% below median its 10-year median of 50.15. Over the past 10 years, this metric has ranged from a low of 32.98 to a high of 64.50. Based on the distribution chart, Genmab AS ranks #96 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #96 out of 944 companies for EBITDA Margin %. This places Genmab AS in the top 10% of its industry — outperforming the majority of peers. Historically, Genmab AS's own EBITDA Margin % has ranged from 32.98 to 64.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genmab AS and its competitors. Genmab AS's current EBITDA Margin % is 24.00%, which is 52% below median its own 10-year median of 50.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current EBITDA Margin % is 24.00%, which is 52% below median its 10-year median of 50.15. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current EBITDA Margin % is 24.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
EBITDA Margin %: 24.00% (52% below median its 10-year median of 50.15)
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
